Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer
Menée à partir d'échantillons tumoraux prélevés sur 24 patientes atteintes d'un cancer de l'ovaire (âge médian : 62 ans), cette étude évalue l'association entre la proportion du stroma tumoral et le risque de résistance aux chimiothérapies à base de sels de platine
Standard treatment for ovarian cancer is platinum-based chemotherapy; however, 15% to 30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. Resistance to platinum-based chemotherapy is a clinical designation, assessed by time to recurrence or progression of malignant disease within 6 months after cessation of platinum-based treatment. Refractory disease is defined as recurrence of disease during the course of platinum-based chemotherapy. There is evidence to support the hypothesis that stromatous components of malignant tumors stimulate growth and proliferation of malignant components of invasive tumors; higher stromal content, referred to as high tumor-stroma proportion, has been associated with worse prognosis in many epithelial cancers. We report the results of a prospective observational study examining tumor-stroma proportion as a predictive biomarker of chemoresistance in women diagnosed with ovarian cancer.
JAMA Oncology , résumé, 2018